Sleep Medicine Reviews
Volume 7, Issue 2 , Pages 115-129 , April 2003

Parkinson's disease and sleep

References 

  1. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol. 1982;5:183–194
  2. van Hilten JJ, Weggeman M, van der Welde EA, Kerkhof GA, van Dijk JG, Roos RAC. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm [P-D Sect]. 1993;5:235–244
  3. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord. 1998;13:895–899
  4. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Movement disorders. 1990;5:280–285
  5. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol. 1988;11:512–519
  6. Wetter TH, Collado-Seidel V, Pollmächer T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep. 2000;23:361–367
  7. Miele V, Proli F, Salzarulo P. Electropolygraphic aspects of sleep in patients with parkinsonism. Riv Sper Freniatr Med Leg Alien Ment. 1970;94:69–82
  8. Kales A, Ansel RD, Markham CH, Scharf MB, Tan TL. Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration. Clin Pharmacol Ther. 1971;12:397–406
  9. Kendel K, Beck U, Wita C, Hohneck E, Zimmermann H. Influence of L -DOPA on night sleep in parkinsonian patients. Arch Psychiatr Nervenkr. 1972;216:82–100
  10. Mouret J. Differences in sleep in patients with Parkinson's disease. Electroencephalogr Clin Neurophysiol. 1975;38:637–673
  11. Traczynska-Kubin D, Atzef E, Petre-Quadens O. Sleep in parkinsonism. Acta Neurol Psychiatr Belg. 1969;69:727–733
  12. Poewe W, Högl B. Parkinson's disease and sleep. Current Opinion in Neurology. 2000;13:426
  13. Ferrini-Strambi L, Franceschi M, Pinto P, Zucconi M, Smirne S. Respiration and heart rate variability during sleep in untreated Parkinson patients. Gerontology. 1992;38:92–92
  14. Hogl BE, Gomez-Arevalo G, Garcia S, Scipioni O, Rubio M, Blanco M, et al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology. 1998;50:1332–1339
  15. Askenasy JJM, Mendelsohn L, Katz A. Basal ganglia disorders with marked circadian fluctuations. [Abstract]. Sleep Research. 1985;14:
  16. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of L -DOPA. J Neural Transm Park Dis Dement Sect. 1993;5:227–234
  17. Askenasy JJ. Sleep in Parkinson's disease. Acta Neurol Scand. 1993;87:167–170
  18. Stern M, Roffwarg H, Duvoisin R. The parkinsonian tremor in sleep. J Nerv Ment Dis. 1968;147:202–210
  19. Fish DR, Sawyers D, Allen PJ, Blackie JD, Lees AJ, Marsden CD. The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. Arch Neurol. 1991;48:210–214
  20. Askenasy JJ, Yahr MD. Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep. J Neurol Neurosurg Psychiatry. 1990;53:749–753
  21. Trenkwalder C. Sleep dysfunction in Parkinson's disease. Clin Neurosci. 1998;5:107–114
  22. Chaudhuri KR, Appiah-Kubi LS, Trenkwalder C. Restless legs syndrome. J Neurol Neurosurg Psychiatry. 2001;71:143–146
  23. Aldrich MS, Kryger M, Roth T, Dement W. Principles and practice of sleep medicine. 3rd ed.. Philadelphia: Saunders; 2000; p. 1051–1057
  24. Askenasy JJ, Yahr MD. Different laws govern motor activity in sleep than in wakefulness. J Neural Transm Gen Sect. 1990;79:102–103
  25. van Hilten B, Hoff JI, Middelkoop HA, van der Velde EA, Kerkhof GA, Wauquier A, et al. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neurol. 1994;51:922–928
  26. Bertolucci PH, Andrade LA, Lima JG, Carlini EA. Total sleep deprivation and Parkinson disease. Arq Neuropsiquiatr. 1987;45:224–230
  27. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology. 2000;55:281–288
  28. Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm. 1978;43:143–151
  29. Klawans HL, Moskovitz C, Nausieda PA, Weiner WJ. Levodopa-induced dopaminergic hypersensitivity in the pathogenesis of psychiatric and neurologic disorders. Int J Neurol. 1979;13:224–225
  30. Schenck CH, Hurwitz TD, Mahowald MW. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res. 1993;2:224–231
  31. Schenck CH, Mahowald MW. REM sleep parasomnias. Neurol Clin. 1996;14:697–720
  32. Schenck CH, Bundlie SR, Patterson AL, Mahowald MW. Rapid eye movement sleep behavior disorder. A treatable parasomnia affecting older adults. JAMA. 1987;257:1786–1789
  33. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol. 1993;34:710–714
  34. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998;51:526–529
  35. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46:388–393
  36. Schenck CH, Milner DM, Hurwitz TD, Bundlie SR, Mahowald MW. A polysomnographic and clinical report on sleep-related injury in 100 adult patients. Am J Psychiatry. 1989;146:1166–1173
  37. The International Classification of Sleep Disorders. Rochester: Diagnostic and Coding Manual; 1990;
  38. Garcia-Borreguero D, Caminero AB, Larrosa O. Decreased phasic activity during REM sleep in untreated Parkinson's disease. [Abstract]. Sleep. 2000;23:
  39. Montplaisir J, Petit D, Filipini D. REM sleep characteristics in patients with Parkinson's disease associated or not with REM sleep behavior disorder. [Abstract]. Sleep. 2000;23:A103
  40. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 1991;50:743–755
  41. Jellinger KA. Post mortem studies in Parkinson's disease – it possible to detect brain areas for specific symptoms?. J Neural Transm. 1999;56:1–29
  42. Askenasy JJ. Sleep in Parkinson's disease. Acta Neurol Scand. 1993;87:167–170
  43. Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep. 1997;29:757–788
  44. Lai YY, Siegel JM. Pontomedullary glutamate receptors mediating locomotion and muscle tone suppression. J Neurosci. 1991;11:2931–2937
  45. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain. 2000;123:1155–1160
  46. Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Movement disorders. 1996;11:214–216
  47. Hardie RJ, Efthimiou J, Stern GM. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1986;50:1326
  48. Greulich W, Schäfer D, Georg WM, Schläfke ME. Sleep behaviour in patients with PD. Somnology. 1998;2:163–171
  49. Hovestadt A, Bogaard JM, Meerwaldt JD, van der Meche FGA, Stigt J. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989;52:329–333
  50. Corbin DO, Williams AC. Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1987;50:821–822
  51. Vincken WG, Gauthier SG, Dollfus RE, Hanson R, Darauay CM, Cosio MG. Involvement of upper-airway muscles in extrapiramidal disorders. A cause of airflow limitation. N Engl J Med. 1984;311:438–442
  52. Fitzpatrick AJ. Upper airway obstruction in Parkinson's disease. Anaesth Intensive Care. 1995;23:367–369
  53. Vincken WG, Darauay CM, Cosio MG. Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease. Chest. 1989;96:210–212
  54. Brescia Morra V, Polverino M, De Luca G, Luca G, Landi P, Galdi A, et al. Upper airway muscles dysfunction and levodopa responsiveness in Parkinson's disease. Acta Neurol (Napoli). 1992;14:512–518
  55. de Bruin PF, de Bruin VM, Lees AJ, Pride NB. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease. Am Rev Respir Dis. 1993;148:1576–1580
  56. Zupnick HM, Brown LK, Miller A, Moros DA. Respiratory dysfunction due to L -DOPA therapy for Parkinsonism: Diagnosis using serial pulmonary function tests and respiratory inductive pletysmograph. Am J Med. 1990;86:109–114
  57. De Keyser J, Vincken W. L -Dopa-induced respiratory disturbance in Parkinson's disease suppressed by tiapride. Neurology. 1985;35:235–237
  58. Riley DE, Grossman G, Martin L. Acute respiratory faillure from dopamine agonist withdrawal. Neurology. 1992;42:1843–1844
  59. Onodera H, Okabe S, Kikuchi Y, Tsuda T, Itoyama Y. Impaired chemosensivity and perception of dyspnoea in Parkinson's disease. Lancet. 2000;356:739–740
  60. Röggla G, Weber W, Röggla M. Parkinson's disease and impaired chemosensitivity to hypoxia. [Abstract]. Lancet. 2000;356:2099
  61. Rosen JM, Feinsilver SH, Friedman JH. Increased CO2 responsiveness in Parkinson's disease: Evidence for a role of CNS dopamine in ventilatory control. [Abstract]. Am Rev Respir Dis. 1985;131:A297
  62. Pal PK, Calne S, Samii A, Fleming JAE. A review of normal sleep and its disturbances in Parkinson's disease. Parkinsonism and Related Disorders. 1999;5:1–17
  63. Goetz, CG, Wilson, RS, Tanner, CM, Yahr, MD, Bergman, KJ, Advances in Neurology: Parkinson's disease, 1986, 345
  64. Kostic VS, Susic V, Przedborski S, Sternic N. Sleep EEG in depressed and nondepressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1991;3:176–179
  65. Menza MA, Rosen RC. Sleep in Parkinson's disease. Psychosomatics. 1995;36:262–266
  66. Whitney CW, Enright PL, Newman AB, Bonekat W, Foley D, Quan SF. Correlates of daytime sleepiness in 4578 elderly persons: the cardiovascular health study. Sleep. 1998;21:27–36
  67. Henderson R, Kurlan R, Kersum JM, Como P. Preliminary examination of the co-morbidity of anxiety and depression in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992;4:257–264
  68. Ondo WG, Dat Vuong K, Vuong K, Khan H, Atassi F, Kwak C, et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57:1392–1396
  69. Carskadon MA. Sleep and alertness. New York: Raven Press; 1989; p. 53
  70. Rye DB, Bliwise DL, Dihenia B, Gurecki P. FAST TRACK: daytime sleepiness in Parkinson's disease. J Sleep Res. 2000;9:63–69
  71. Rye DB, Johnston LH, Watts RL, Bliwise DL. Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset. Neurology. 1999;53:1868–1870
  72. Chaudhuri KR, Ellis C, Love-Jones S, Thomaides T, Clift S, Mathias CJ, et al. Postprandial hypotension and parkinsonian state in Parkinson's disease. Mov Disord. 1997;12:877–884
  73. Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1:49–61
  74. Galarraga E, Corsi-Cabrera M, Sangri M. Reduction in paradoxical sleep after L -dopa administration in rats. [Abstract]. Behav Neural Biol. 1986;46:249–256
  75. Boivin DB, Montplaisir J. The effects of L -DOPA on excessive daytime sleepiness in narcolepsy. Neurology. 1991;41:1267–1269
  76. Gillin JC, Post RM, Wyatt RJ, Snyder F, Bunney WE. REM inhibitory effect of L -DOPA infusion during human sleep. Electroencephalogr Clin Neurophysiol. 1973;35:181–186
  77. Nakazawa Y, Tachibana H, Kotorii M, Ogata M. Effects of L -DOPA on natural night sleep and on rebound of REM sleep. Folia Psychiatr Neurol Jpn. 2001;27:223–230
  78. Boivin DB, Montplaisir J, Poirier G. The effects of L -DOPA on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol. 1989;12:339–345
  79. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf. 2001;24:863–868
  80. Montastruc JL, Brefel-Courbon C, Senard JM, Bagheri H, Ferreira J, Rascol O, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol. 2001;24:181–183
  81. Trampus M, Ferri N, Monopoli A, Ongini E. The dopamine D1 receptor is involved in the regulation of REM sleep in the rat. Eur J Pharmacol. 1991;194:189–194
  82. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–1910
  83. Olanow CW, Schapira AH, Roth T. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole. Neurology. 2000;54:274
  84. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord. 2000;15:212–215
  85. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Mignot E. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res. 1996;733:83–100
  86. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000;15:658–663
  87. Reyner LA, Horne JA. Falling asleep whilst driving: are drivers aware of prior sleepiness?. Int J Legal Med. 1998;111:120–123
  88. Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm. 2001;108:71–77
  89. Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet. 2000;355:1332–1333
  90. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet. 2000;355:1333–1334
  91. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology. 1994;44:2095–2101
  92. Arnulf I, Bejjani BP, Garma L, Bonnet AM, Houeto JL, Damier P, et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology. 2000;55:1732–1734
  93. Parkes JD. Variability in Parkinson's disease: clinical aspects, causes and treatment. Acta Neurol Scand. 1983;68:27–35
  94. Comella CL, Stebbins GT, Bohmer J. Sleep benefit in Parkinson's disease. [Abstract]. Neurology. 1995;45:A286
  95. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations?. Neurology. 1988;38:1553–1557
  96. Nutt JG, Carter JH, Woodward WRT. Diurnal patterns of motor function in Parkinson's disease. [Abstract]. Neurology. 1997;48:A75
  97. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease. Imposing pharmacological law and order. Ann Neurol. 1996;39:561–573
  98. Currie LJ, Bennett JP, Harrison MB, Trugman JM, Wooten GF. Clinical correlates of sleep benefit in Parkinson's disease. Neurology. 1997;48:1115–1117
  99. Bliwise D, Rye D, Dihenia B. Periodic leg movements in elderly patients with parkinsonism. Sleep. 1998;21:196–200
  100. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993;6:602–608
  101. Jouvet M, Delorme JF. Locus coeruleus et somneil paradoxal. C R Soc Biol. 1965;159:895–899
  102. Garcia-Rill E. The pedunculopontine nucleus. Prog Neurobiol. 1991;36:363–389
  103. Lai YY, Siegel JM. Muscle tone suppression and stepping produced by stimulation of midbrain and rostral pontine reticular formation. J Neurosci. 1990;10:2727–2734
  104. Shouse MN, Siegel JM. Pontine regulation of REM sleep components in cats: integrity of the pedunculopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep. Brain Res. 1992;571:50–63
  105. Zarcone VPJ, Kryger MH, Roth T, Dement WC. Principles and practice of sleep medicine. 3rd ed. Sleep hygiene. Philadelphia: Saunders; 2000; p. 657–661
  106. Dorsey CM, Lukas SE, Teicher MH, Harper D, Winkelman JW, Cunningham SL, et al. Effects of passive body heating on the sleep of older female insomniacs. J Geriatr Psychiatry Neurol. 1996;9:83–90
  107. Dorsey CM, Teicher MH, Cohen-Zion M, Satlin A, Tartarini W, Harper D, et al. Core body temperature and sleep of older female insomniacs before and after passive body heating. Sleep. 1999;22:891–898
  108. Ray Chaudhuri K, Bhattacharya K, Porter MC, Mills J, Clough C. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: a parallel study with controlled release levodopa. Eur J Neurol. 1999;6:S11–S15
  109. Reuter I, Ellis CM, Chaudhuri K Ray. Use of subcutaneous apomorphine infusion for refractory nocturnal disabilities in Parkinson's disease including restless leg syndrome. Acta Neurol Scand. 1999;100:163–167
  110. Ghatani T, Agapito C, Bhattacharya K, Clough C, Chaudhuri K Ray. Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal “off” periods causing sleep disruption in Parkinson's disease. Euro J Neurol. 2001;8:8–11
  111. Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinations in advanced Parkinson's disease. Lancet. 1993;341:562–563
  112. Schenck CH, Hurwitz TD, Mahowald MW. REM sleep behavior disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res. 1993;2:224–231
  113. Rye DB, Bliwise DL, Watts RL, Koller WC. Movement disorders: neurologic principles and practice. Movement Disorders Specific to Sleep and the Nocturnal Manifestations of Waking Movement Disorders. New York: McGraw-Hill; 1997; p. 687–693
  114. Walters AS. Toward a better definition of the restless legs syndrome. Movement Disorders. 1995;634–642
  115. Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol. 2001;248:632–634
  116. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole- associated somnolence. Mov Disord. 2000;15:1269–1271

PII: S1087-0792(02)90229-7

doi: 10.1053/smrv.2002.0229

Sleep Medicine Reviews
Volume 7, Issue 2 , Pages 115-129 , April 2003

Article Tools